AR100732A1 - Derivados aminoéster sustituidos con quinuclidina - Google Patents
Derivados aminoéster sustituidos con quinuclidinaInfo
- Publication number
- AR100732A1 AR100732A1 ARP150101772A ARP150101772A AR100732A1 AR 100732 A1 AR100732 A1 AR 100732A1 AR P150101772 A ARP150101772 A AR P150101772A AR P150101772 A ARP150101772 A AR P150101772A AR 100732 A1 AR100732 A1 AR 100732A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- hydrogen
- optionally substituted
- diyl
- Prior art date
Links
- 229910052739 hydrogen Inorganic materials 0.000 abstract 11
- 239000001257 hydrogen Substances 0.000 abstract 11
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 7
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 6
- -1 indan-1,1-diyl Chemical group 0.000 abstract 6
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 abstract 2
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 2
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- PKTJKKARCIJTJR-UHFFFAOYSA-N 2,2-difluoro-1,3-dioxolane Chemical group FC1(F)OCCO1 PKTJKKARCIJTJR-UHFFFAOYSA-N 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 229940122694 Muscarinic M3 receptor antagonist Drugs 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000000732 arylene group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 239000002532 enzyme inhibitor Substances 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005549 heteroarylene group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 125000006588 heterocycloalkylene group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 239000003681 muscarinic M3 receptor antagonist Substances 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La presente se relaciona con compuestos que son tanto inhibidores de la enzima fosfodiesterasa 4 (PDE4) como antagonistas de receptor M3 muscarínico, métodos para preparar dichos compuestos, composiciones que los contienen. Reivindicación 1: Un compuesto caracterizado porque es de fórmula general (1) donde cada R¹ es hidrógeno o se selecciona en forma independiente entre el grupo que consiste en: halógeno, C₁₋₄ alquilo, C₁₋₄ alcoxi, C₁₋₄ haloalquilo, hidroxi, -SO₂NRIRII, -CN, -NRISO₂RIII, -NRIRII, -(CO)NRIRII y -NRI(CO)RIII, y donde dicho C₁₋₄ alquilo está opcionalmente sustituido con uno o más grupos seleccionados entre C₃₋₇ cicloalquilo, hidroxi y -NRIRII y donde dicho C₁₋₄ alcoxi está opcionalmente sustituido con uno o más halógenos o grupos C₃₋₇ cicloalquilo donde, RI es hidrógeno o C₁₋₆ alquilo; RII es hidrógeno o C₁₋₆ alquilo; RIII es hidrógeno o C₁₋₆ alquilo; n es un entero en el rango de 1 a 3; cada R² es hidrógeno o se selecciona en forma independiente entre el grupo que consiste en: halógeno, C₁₋₄ alquilo, C₁₋₄ alcoxi, C₁₋₄ haloalquilo, hidroxi, -SO₂NRIRII, -CN, -NRISO₂RIII, -NRIRII, -(CO)NRIRII y -NRI(CO)RIII y donde dicho C₁₋₄ alquilo está opcionalmente sustituido con uno o más grupos seleccionados entre C₃₋₇ cicloalquilo, hidroxi y -NRIRII y donde dicho C₁₋₄ alcoxi está opcionalmente sustituido con uno o más halógenos o grupos C₃₋₇ cicloalquilo donde, RI es hidrógeno o C₁₋₆ alquilo; RII es hidrógeno o C₁₋₆ alquilo; RIII es hidrógeno o C₁₋₆ alquilo; m es un entero en el rango de 1 a 3; R³ y R⁴ son diferentes o iguales y se seleccionan en forma independiente entre el grupo que consiste en: H, C₃₋₇ cicloalquilcarbonilo, C₁₋₆ alquilo opcionalmente sustituido con uno o más sustituyentes seleccionados entre C₃₋₇ cicloalquilo y C₅₋₇ cicloalquenilo, C₁₋₆ haloalquilo, C₃₋₇ cicloalquilo, C₅₋₇ cicloalquenilo, C₂₋₅ alquenilo, y C₂₋₆ alquinilo; o R³ y R⁴, junto con los átomos que los conectan, forman un anillo 2,2-difluoro-1,3-dioxolano de fórmula (2) fusionado a la unidad fenilo que se une a los grupos -OR³ y -OR⁴, donde los asteriscos indican átomos de carbono compartidos con dicho anillo fenilo; cada R⁵ se selecciona entre el grupo que consiste en: CN, NO₂, CF₃ y átomos de halógeno; k es 0 o un entero en el rango de 1 a 3; x es 0 ó 1; L¹ se selecciona entre una unión y -(CH₂)ₚ- donde p es un entero en el rango de 1 a 4; W¹ se selecciona entre un grupo arileno, heteroarileno y heterocicloalquileno monocíclico saturado divalente; L² es un grupo seleccionado entre: una unión, -(CH₂)q- donde q es 1 ó 2, [1]-(CO)-[X]-(CH₂)ₜ-[2], y [1]-(SO₂)-[X]-(CH₂)ₜ-[2], donde [1] y [2] representan respectivamente el punto de unión del grupo L² al anillo W¹ y al átomo de nitrógeno de la cadena, y donde [X] es una unión o un grupo arileno sustituido o no sustituido; t es un entero en el rango de 1 a 4; W² se selecciona entre un grupo arilo y heteroarilo; L es una unión o un grupo -(CH₂)-; R⁶ se selecciona entre el grupo que consiste en C₁₋₄ alquilo, C₁₋₄ alcoxi, C₁₋₄ haloalquilo, y -CN, donde dicho C₁₋₄ alquilo está opcionalmente sustituido con uno o más grupos seleccionados entre C₃₋₇ cicloalquilo, C₁₋₄ alcoxilo y hidroxilo, o, como alternativa, cuando R⁶ es C₁₋₄ alquilo, W² es un anillo fenilo, uno de R¹ es un alquilo en posición orto con respecto a L, R¹ y R⁶ pueden estar conectados para formar con W² un radical de anillo condensado seleccionado entre al menos 1H-ciclopropabencen-1,1-diilo, indan-1,1-diilo (también llamado 2,3-dihidro-1H-inden-1,1-diilo), indan-2,2-diilo (también llamado 2,3-dihidro-1H-inden-2,2-diilo), 1,2,3,4-tetrahidronaftalen-1,1-diilo, y 1,2,3,4-tetrahidronaftalen-2,2-diilo; R⁷ se selecciona entre hidrógeno y C₁₋₄ alquilo opcionalmente sustituido con hidroxi o -NR¹¹R¹² y donde R¹¹ y R¹² se seleccionan en forma independiente entre hidrógeno, C₁₋₄ alquilo, o, junto con el átomo de nitrógeno al que se unen pueden formar un grupo heterocicloalquilo saturado que tiene un heteroátomo adicional seleccionado entre O, S y NH; A es un grupo que contiene nitrógeno que puede seleccionarse entre: un grupo (a) que es -(CH₂)ₛ-NR⁸R⁹ donde s es un entero en el rango de 1 a 4 y R⁸ y R⁹ son en forma independiente hidrógeno o C₁₋₄ alquilo; y un grupo (b) que es un sistema de anillos heterocíclico saturado monocíclico, bicíclico o tricíclico opcionalmente sustituido con uno o dos grupos R¹⁰ que se seleccionan en forma independiente entre sí entre C₁₋₄ alquilo y bencilo; derivados deuterados, y sales o solvatos farmacéuticamente aceptables del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14171266 | 2014-06-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR100732A1 true AR100732A1 (es) | 2016-10-26 |
Family
ID=50884281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150101772A AR100732A1 (es) | 2014-06-05 | 2015-06-04 | Derivados aminoéster sustituidos con quinuclidina |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US9763924B2 (es) |
| EP (1) | EP3152201B1 (es) |
| JP (1) | JP2017516824A (es) |
| KR (1) | KR102420323B1 (es) |
| CN (1) | CN106459020B (es) |
| AR (1) | AR100732A1 (es) |
| AU (1) | AU2015270539B2 (es) |
| BR (1) | BR112016026725B1 (es) |
| CA (1) | CA2953198C (es) |
| CL (1) | CL2016003117A1 (es) |
| CY (1) | CY1120698T1 (es) |
| DK (1) | DK3152201T3 (es) |
| EA (1) | EA032761B1 (es) |
| ES (1) | ES2688826T3 (es) |
| GE (1) | GEP20186922B (es) |
| HR (1) | HRP20181967T1 (es) |
| HU (1) | HUE042119T2 (es) |
| IL (1) | IL249325B (es) |
| LT (1) | LT3152201T (es) |
| MA (1) | MA39947B1 (es) |
| MX (1) | MX2016015958A (es) |
| PE (1) | PE20161557A1 (es) |
| PH (1) | PH12016502221A1 (es) |
| PL (1) | PL3152201T3 (es) |
| PT (1) | PT3152201T (es) |
| RS (1) | RS57787B1 (es) |
| SG (1) | SG11201610132RA (es) |
| SI (1) | SI3152201T1 (es) |
| TN (1) | TN2016000546A1 (es) |
| TW (1) | TW201625600A (es) |
| WO (1) | WO2015185649A1 (es) |
| ZA (1) | ZA201608331B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA42048A (fr) | 2015-05-07 | 2018-03-14 | Chiesi Farm Spa | Dérivés d'aminoesters |
| AR104822A1 (es) * | 2015-06-01 | 2017-08-16 | Chiesi Farm Spa | Derivado de aminoésteres |
| TW201710254A (zh) * | 2015-06-01 | 2017-03-16 | 吉斯藥品公司 | 胺基酯衍生物 |
| CN106866474B (zh) * | 2017-02-16 | 2018-12-28 | 陕西师范大学 | 一种手性α-芳基甘氨酸酯衍生物的合成方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2022783A1 (en) * | 2007-08-08 | 2009-02-11 | CHIESI FARMACEUTICI S.p.A. | "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors" |
| PE20091552A1 (es) * | 2008-02-06 | 2009-10-25 | Glaxo Group Ltd | Farmacoforos duales - antagonistas muscarinicos de pde4 |
| EP2216327A1 (en) | 2009-02-06 | 2010-08-11 | CHIESI FARMACEUTICI S.p.A. | Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors |
| CN104822669A (zh) * | 2012-12-05 | 2015-08-05 | 奇斯药制品公司 | 作为pde-4抑制剂的苯基乙基吡啶衍生物 |
| CN104822671B (zh) | 2012-12-05 | 2017-10-31 | 奇斯药制品公司 | 作为pde4抑制剂的苯乙基吡啶衍生物 |
| RU2015121043A (ru) | 2012-12-05 | 2017-01-11 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Производные фенилэтилпиридина в качестве ингибиторов PDE-4 |
| RU2016121854A (ru) * | 2013-12-05 | 2017-12-07 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Производные гетероарила |
| US9145409B2 (en) | 2013-12-05 | 2015-09-29 | Chiesi Farmaceutici S.P.A | Benzhydryl derivatives |
-
2015
- 2015-05-28 US US14/723,964 patent/US9763924B2/en active Active
- 2015-06-03 BR BR112016026725-7A patent/BR112016026725B1/pt active IP Right Grant
- 2015-06-03 MX MX2016015958A patent/MX2016015958A/es active IP Right Grant
- 2015-06-03 KR KR1020167032346A patent/KR102420323B1/ko active IP Right Grant
- 2015-06-03 EA EA201692227A patent/EA032761B1/ru not_active IP Right Cessation
- 2015-06-03 RS RS20181192A patent/RS57787B1/sr unknown
- 2015-06-03 ES ES15731261.2T patent/ES2688826T3/es active Active
- 2015-06-03 CN CN201580029748.7A patent/CN106459020B/zh active Active
- 2015-06-03 SI SI201530392T patent/SI3152201T1/sl unknown
- 2015-06-03 JP JP2016571037A patent/JP2017516824A/ja not_active Withdrawn
- 2015-06-03 CA CA2953198A patent/CA2953198C/en active Active
- 2015-06-03 PL PL15731261T patent/PL3152201T3/pl unknown
- 2015-06-03 PE PE2016002520A patent/PE20161557A1/es unknown
- 2015-06-03 TN TN2016000546A patent/TN2016000546A1/en unknown
- 2015-06-03 MA MA39947A patent/MA39947B1/fr unknown
- 2015-06-03 DK DK15731261.2T patent/DK3152201T3/en active
- 2015-06-03 HU HUE15731261A patent/HUE042119T2/hu unknown
- 2015-06-03 GE GEAP201514338A patent/GEP20186922B/en unknown
- 2015-06-03 EP EP15731261.2A patent/EP3152201B1/en active Active
- 2015-06-03 LT LTEP15731261.2T patent/LT3152201T/lt unknown
- 2015-06-03 SG SG11201610132RA patent/SG11201610132RA/en unknown
- 2015-06-03 WO PCT/EP2015/062417 patent/WO2015185649A1/en active Application Filing
- 2015-06-03 AU AU2015270539A patent/AU2015270539B2/en not_active Expired - Fee Related
- 2015-06-03 PT PT15731261T patent/PT3152201T/pt unknown
- 2015-06-04 AR ARP150101772A patent/AR100732A1/es unknown
- 2015-06-04 TW TW104118107A patent/TW201625600A/zh unknown
-
2016
- 2016-11-09 PH PH12016502221A patent/PH12016502221A1/en unknown
- 2016-12-01 IL IL249325A patent/IL249325B/en not_active IP Right Cessation
- 2016-12-02 ZA ZA2016/08331A patent/ZA201608331B/en unknown
- 2016-12-02 CL CL2016003117A patent/CL2016003117A1/es unknown
-
2017
- 2017-08-10 US US15/673,710 patent/US10117860B2/en active Active
-
2018
- 2018-09-24 CY CY181100984T patent/CY1120698T1/el unknown
- 2018-11-23 HR HRP20181967TT patent/HRP20181967T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR120338A1 (es) | Piridazinonas como inhibidores de parp7 | |
| AR100059A1 (es) | Compuestos útiles como inmunomoduladores | |
| AR111295A1 (es) | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) | |
| AR116109A1 (es) | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos | |
| AR099367A1 (es) | Inhibidores de la tirosina quinasa de bruton | |
| AR112529A1 (es) | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos en el tratamiento de diversos tipos de cáncer | |
| AR103990A1 (es) | Ureas cíclicas como inhibidoras de rock | |
| AR091981A1 (es) | Dihidropiridona p1 como inhibidores del factor xia | |
| AR104884A1 (es) | Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj | |
| AR093364A1 (es) | Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso | |
| AR107061A1 (es) | Heteroarilhidroxipirimidinonas como agonistas del receptor de apj | |
| AR096788A1 (es) | Compuestos tricíclicos de carboxamida como inhibidores potentes de rock | |
| AR108011A1 (es) | Moduladores receptores de estrógenos | |
| AR093795A1 (es) | Oxidos de piridinio, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades respiratorias | |
| AR089865A1 (es) | Derivados de bencimidazol e imidazopiridinas como moduladores de canales de sodio | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| AR093797A1 (es) | Derivados de feniletilpiridina inhibidores de pde-4 | |
| AR100732A1 (es) | Derivados aminoéster sustituidos con quinuclidina | |
| AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
| AR100807A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR110282A1 (es) | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 | |
| AR092288A1 (es) | Ligandos del receptor ep1 | |
| AR098621A1 (es) | Derivados de heteroarilo | |
| AR093798A1 (es) | Compuestos | |
| AR110498A1 (es) | DERIVADOS DE ISOXAZOLIL ÉTER COMO MODULADORES ALOSTÉRICOS POSITIVOS (PAM) DE RECEPTORES DE GABAA a5 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |